Wells Fargo Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43

Moomoo NewsNov 21 05:34 ET · Ratings

Septerna | 10-Q: Quarterly report

SECNov 20 16:22 ET · Announcements

Septerna | 8-K: Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SECNov 20 16:13 ET

Express News | Septerna-Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, With Data Expected in Mid-2025

ReutersNov 20 16:13 ET

TD Cowen Maintains Septerna(SEPN.US) With Buy Rating

Moomoo NewsNov 20 11:31 ET · Ratings

Septerna's Q3 Loss Widens, Revenue Rises

MT NewswiresNov 20 07:53 ET